Infertility,Female
Conditions
Keywords
IVF, Platelet-rich plasma, Granulocyte colony-stimulating factor, Recurrent implantation failure
Brief summary
The aim of this randomized controlled trial is to determine whether granulocyte colony-stimulating factor and platelet-rich plasma can be used to enhance the IVF-ET outcomes in patients with recurrent implantation failure
Interventions
DRUGGranulocyte colony-stimulating factor and platelet-rich plasma group
Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
OTHERControl group
Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
Sponsors
Riyadh Fertility and Reproductive Health center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
1 Years to 35 Years
Healthy volunteers
No
Inclusion criteria
• Patients with history of three or more unsuccessful IVF-ET cycles with at least 2 good quality embryos transferred
Exclusion criteria
* Endometriosis * Uterine anomalies * Asherman syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical pregnancy rate | Five weeks after embryo transfer | Gestational sac detected by ultrasound examination |
Countries
Egypt
Contacts
Primary ContactUsama M Fouda, Prof.
Outcome results
None listed